“roche” Archives

in
Entry Author Date Location
Adieu to Adu: Biogen’s Big Alzheimer’s Bet Flops, Shares Routed 03/21/19 Boston
Pfizer Bolsters Gene Therapy Position with $51M Vivet Deal 03/20/19 New York
Dermira Shares Soar After Eczema Drug Hits Goal of Mid-Stage Study 03/18/19 San Francisco
Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More 03/15/19 National
San Diego Life Sciences Roundup: ResMed, Alexandria GradLabs & More 03/08/19 San Diego
After AGTC Deal Flops, Biogen Bets $800M on Gene Therapy Rival Nightstar 03/04/19 Boston
Bio Roundup: Pharma in DC, Bristol-Cel in Trouble, Roche Gets A Spark 03/01/19 National
Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy 02/25/19 National
Merck Scooping Up Cancer Drug Developer Immune Design for $300M 02/21/19 New York
Halozyme Gets $30M from Argenx in Licensing Deal Worth Up to $530M 02/06/19 San Diego
FDA Rejects Alkermes Depression Drug, Asks for More Clinical Data 02/01/19 Boston
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More 02/01/19 National
All Eyes on Biogen as Roche Alzheimer’s Drug Flunks Final Test 01/30/19 National
Healthcare Technology Bubble Concerns Are Likely Overblown 01/28/19 Boston
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More 01/25/19 National
In Another Lung Cancer Setback, Bristol Yanks FDA App For Drug Combo 01/24/19 New York
Failed Clinical Trial Puts Eli Lilly Cancer Drug in Limbo 01/18/19 Indiana
Merck And The Future of Immuno-Oncology: A Chat With Roger Perlmutter 01/16/19 National
Genentech, Adaptive Bio Join Forces on Personalized Cancer Drugs R&D 01/04/19 Seattle
Forge Therapeutics Gets up to $11.1M to Advance “Superbug” Drugs 01/03/19 San Diego
Tizona Lands $105M from AbbVie in Cancer Drug R&D Alliance 01/03/19 San Francisco
Ligand Inks Deal, Ionis Details Succession Plan, & More SD Biotech 12/21/18 San Diego
Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More 12/21/18 National
With $42M, Ex-Ignyta CEO Aims At Cancer Again With Startup, Erasca 12/18/18 San Diego
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
15 for ’19: Key Clinical Data to Watch for Next Year (Part 1) 12/17/18 National
Roche Vet O’Day Tapped to Shape Gilead’s Future as Hep C Sales Fall 12/10/18 San Francisco
Bio Roundup: ASH Wrap, CRISPR Baby Fallout, Moderna’s Record IPO 12/07/18 National
Genetic Medicine: FDA OKs 2nd Cancer Drug That Targets DNA, Not Tissues 11/26/18 National
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More 11/26/18 National
Page 1 of 22 next page »